Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2017

View Archived Issues

AmorChem Holdings spins out two new companies

Silence Therapeutics acquires equity stake in Arrowhead Pharmaceuticals

Allergan licenses rights to Assembly Biosciences' microbiome programs

FDA accepts Adaptimmune's IND for T-cell therapy targeting MAGE-A4

Vescor formed to develop autophagy therapeutics

FASN inhibitors reported in Teva patent

Chongqing University reports PDE5A inhibitors

NeuroVive, Karolinska Institutet enter collaboration for cyclophilin inhibitor

Moderna Therapeutics: developing mRNA therapeutics

Lumason obtains FDA approval for the use in ultrasonography

Servier and Vernalis jointly patent Mcl-1 inhibitors

Shionogi's cefiderocol shows positive results in cUTI study

Novartis to conduct phase II study of bimagrumab

EC approves Novo Nordisk's Fiasp for diabetes

Amgen and Immatics Biotechnologies collaborate on novel bispecific cancer immunotherapies

Bayer describes BUB1 inhibitors for cancer

Wockhardt reports antibacterial activity enhancers

Tasly Pharmaceutical describes platelet aggregation inhibitors

Crinetics Pharmaceuticals presents somatostatin receptor agonists

Update on clinical trials of dendritic cell vaccine TLP0-001

Takara Bio applies to conduct Japanese phase I/II study of CAR therapy

Protein Sciences Zika vaccine shows good safety results in preclinical studies

Phase I results from ZUMA-1 trial of KTE-C19 in patients with refractory DLBCL

MedImmune initiates phase I/Ib study of MEDI-3726 in metastatic castration-resistant prostate cancer

CRISPR Cas9 gene repair strategy shows promise for treatment of X-CGD

ViraCyte's T-cell immunotherapy wins FDA fast track, orphan designations

Heron Therapeutics submits NDA for Cinvanti in U.S.

Phase I trial explores MK-7684 alone and in combination with pembolizumab in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.